The Effectiveness and Safety of Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04218500 |
Recruitment Status :
Completed
First Posted : January 6, 2020
Last Update Posted : January 6, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Contact Dermatitis of Hands | Other: Niacinamide 4% Other: Virgin Coconut oil 30% | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 92 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | There were 46 subjects in the niacinamide 4% arm and 46 subjects in the VCO 30% arm |
Masking: | Double (Participant, Investigator) |
Masking Description: | Both moisturizers have the same physical characteristics, with the same color and odor. Randomization was carried out by other than researcher (statistical adviser) |
Primary Purpose: | Prevention |
Official Title: | Comparison of the Effectiveness and Safety Between Moisturizing Cream Containing Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Hermatitis in Intensive Care Unit Nurses: a Double Blind Randomized Clinical Trial |
Actual Study Start Date : | September 3, 2019 |
Actual Primary Completion Date : | October 15, 2019 |
Actual Study Completion Date : | December 31, 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Niacinamide 4%
Niacinamide 4%, applied twice daily for 28 days
|
Other: Niacinamide 4%
cream moisturizer |
Active Comparator: Virgin coconut oil 30%
Virgin coconut oil 30%, applied twice daily for 28 days
|
Other: Virgin Coconut oil 30%
cream moisturizer |
- HECSI [ Time Frame: 14 days ]Hand eczema severity index (HECSI) is a score to indicate the severity of hand dermatitis. The range of HECSI score is 0-360. The HECSI score before treatment was expected to be higher than after treatment. Outcome: change of HECSI
- HECSI [ Time Frame: 28 days ]Hand eczema severity index (HECSI) is a score to indicate the severity of hand dermatitis. The range of HECSI score is 0-360. The HECSI score before treatment was expected to be higher than after treatment. Outcome: change of HECSI
- TEWL [ Time Frame: 14 days ]Trans Epidermal Waterloss (TEWL) is the primary parameter which measured for the skin barrier function, when the skin barrier is damaged the skin will be disrupted in maintaining water. Passive water diffusion via the Corneal stratum. TEWL is measured in g/h/m2. The TEWL value before treatment was expected to be higher than after treatment. Outcome: change of TEWL
- TEWL [ Time Frame: 28 days ]Trans Epidermal Waterloss (TEWL) is the primary parameter which measured for the skin barrier function, when the skin barrier is damaged the skin will be disrupted in maintaining water. Passive water diffusion via the Corneal stratum. TEWL is measured in g/h/m2. TEWL value before treatment was expected to be higher than after treatment. Outcome: change of TEWL
- SCap [ Time Frame: 14 days ]Skin Capasitance (SCap) is a score for skin hidration. SCap can be done with measuring the water level in corneal stratum using non-invasive electric method which measure the capacitance. SCap is measured in Arbitrary Unit (AU). SCap value before treatment was expected to be lower than after treatment. Outcome: change of SCap
- SCap [ Time Frame: 28 days ]Skin Capasitance (SCap) is a score for skin hidration. SCap can be done with measuring the water level in corneal stratum using non-invasive electric method which measure the capacitance. SCap is measured in Arbitrary Unit (AU). SCap value before treatment was expected to be lower than after treatment. Outcome: change of SCap.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 58 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
ICU nurses who:
- Sign the informed consent of the study after receiving explanation before all activity related with this study begin.
- Has Occupation Hand Dermatitis that fulfill the Mathias criteria with dermatitis severity mild to moderate which the score is 1, 2 or 3 corresponding with Investigator Global Assesment (IGA)
- Agree to follow the study protocol
Exclusion Criteria:
- History of allergic or irritate by Niacinamide or VCO or other component in moisturizer
- Receiving medium to high potency of topical Corticosteroid or systemic immunosupresant therapy or history of oral corticosteroid therapy in the last 1 month
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04218500
Indonesia | |
Faculty of Medicine, Universitas Indonesia | |
Jakarta Pusat, Jakarta, Indonesia, 10430 |
Principal Investigator: | Dermatology and Venereology Departement | Fakultas Kedokteran Universitas Indonesia |
Responsible Party: | Yenny Rachmawati, Principal investigator, Indonesia University |
ClinicalTrials.gov Identifier: | NCT04218500 |
Other Study ID Numbers: |
IndonesiaDV |
First Posted: | January 6, 2020 Key Record Dates |
Last Update Posted: | January 6, 2020 |
Last Verified: | September 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Occupational Hand Dermatitis Moisturizer Niacinamide Virgin coconut oil |
HECSI TEWL SCap |
Dermatitis Dermatitis, Contact Skin Diseases Skin Diseases, Eczematous Niacinamide Niacin Nicotinic Acids Vitamin B Complex |
Vitamins Micronutrients Physiological Effects of Drugs Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Vasodilator Agents |